Ikerian AG, a Bern, Switzerland-based parent company of RetinAI U.S., developer of software solutions for medical image and data management, and artificial intelligence (AI) in healthcare, raised USD 6.18M in Series A extension funding.
The round was led by the corporate venture capital arm of Topcon Healthcare, Inc. The first close in 2023 added Zürcher Kantonalbank (ZKB) as a new investor alongside existing Seed and Series A venture firms, the btov Industrial Technologies fund, managed by Matterwave Ventures, Verve Ventures, and private investors.
This Series A Extension brings to USD 11.66M (CHF 10.66M) the total equity raised including the Seed and Series A rounds.
The company intends to use the funds to support continued development and commercial roll out of RetinAI Discovery® in ophthalmology and optometry and for its expansion into new therapeutic areas prioritizing neurodegenerative disorders, vascular conditions and rare diseases.
As part of the financing, and to facilitate its evolution and growth, the company has concluded its corporate restructuring commenced in 2023, to spearhead development beyond ophthalmology with RetinAI Medical AG rebranded as Ikerian AG, and wholly-owned subsidiary RetinAI U.S. Inc. focused on the ophthalmology market.
Led by CEO Dr. Carlos Ciller, Ikerian AG (formerly RetinAI Medical AG), and its subsidiary, RetinAI U.S., develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision.
Focused on the ophthalmology and optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. Its international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases.
Commenting on the news, Carlos Ciller said: “The successful closing of this financing confirms the importance of our AI technology to re-invent workflows for clinical and pharmaceutical research to support more efficient and effective patient care. These funds will allow us to expedite development efforts of our RetinAI Discovery® platform and our pipeline of AI technologies, and to collaborate with Topcon Healthcare and the industry to advance AI in ophthalmology and beyond.”
FinSMEs
02/05/2024